All the same old argument. PFS is the gold standard. If the trial doesn't meet that standard, it fails. No exceptions. OS results don't matter, regardless of the results. Also did a little research on the authors/contributors and found some receive compensation or honorarium from some of the big pharma's that would benefit from DCx-L's failure.
Yep, not peer reviewed. That is the difference between a paper and an article.
And 2 points for the name calling. It becomes you.
So the conflict of interest doesn't count in your articles? Interesting how it seems to be important if you don't like the paper but is unimportant when you like the article.
Market Data 
Markets 
AI
